New therapeutic options for chemotherapy-resistant metastatic breast cancer: the epothilones

Drugs
Paolo Pronzato

Abstract

When taxanes were introduced as anticancer agents some 20 years ago, their broad spectrum of activity was striking and engendered renewed hope for cancer patients. However, they were not without their problems, including a susceptibility to drug resistance caused by the drug efflux pump protein, P-glycoprotein. The epothilones are a new class of chemotherapeutic agents that have a mechanism of action similar enough to the taxanes to retain their broad spectrum of activity, but different enough to escape the multidrug resistance caused by P-glycoprotein. These properties are especially promising for patients with metastatic breast cancer who have run out of therapeutic options as a result of multidrug resistance. Ixabepilone, a semi-synthetic analogue of epothilone B, has recently been granted US FDA approval for the treatment of chemotherapy-resistant advanced breast cancer. Approval was based on results from a phase III study of ixabepilone in combination with capecitabine, as well as phase II studies of ixabepilone monotherapy. Significantly prolonged progression-free survival and increased objective response rates were demonstrated in the phase III study when ixabepilone was administered in combination with capecitabine comp...Continue Reading

References

Nov 1, 1991·Pharmacology & Therapeutics·F Cabral, S B Barlow
May 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·K UedaI Pastan
Apr 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·A V GudkovI B Roninson
Aug 5, 1998·Proceedings of the National Academy of Sciences of the United States of America·T C ChouS J Danishefsky
Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C Dumontet, B I Sikic
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J L BlumT Griffin
Mar 12, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F CardosoM J Piccart
Apr 8, 2003·Current Medicinal Chemistry. Anti-cancer Agents·M Wartmann, K-H Altmann
May 2, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jame AbrahamTito Fojo
Dec 24, 2003·Cancer·Sharon H GiordanoGabriel N Hortobagyi
Feb 14, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P FumoleauM Namer
Feb 24, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sridhar ManiSusan Band Horwitz
May 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Susan GoodinEric H Rubin
May 2, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James J LeeSandra M Swain
Apr 5, 2007·The Oncologist·Javier Cortes, Jose Baselga
Jun 22, 2007·Anti-cancer Drugs·Laura G EstevezJesús García Mata
Jul 4, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Luca Gianni
Jul 4, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Neelima DenduluriSandra M Swain
Jul 4, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henri RochéHervé Curé
Jul 4, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edith A PerezGabriel N Hortobagyi
Jul 4, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eva ThomasMiguel Martin
Oct 31, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eva S ThomasHenri H Roché

❮ Previous
Next ❯

Citations

Apr 24, 2009·Natural Product Reports·Chad D Hopkins, Peter Wipf
Sep 6, 2011·European Journal of Medicinal Chemistry·Bhuwan B Mishra, Vinod K Tiwari
Nov 26, 2009·Clinical Breast Cancer·Carlos A Castaneda, Henry L Gómez
Nov 4, 2009·Cancer Treatment Reviews·Yolanda FernándezLaura García-Estévez
Mar 21, 2013·The Annals of Pharmacotherapy·Michael J SantiagoKenneth H Butler
Apr 22, 2009·Journal of Neuro-oncology·Antonio SilvaniAndrea Salmaggi
Jun 26, 2018·Advanced Science·Yinnan Chen, Yanmin Zhang
May 10, 2019·Microbial Biotechnology·Peng ZhangYue-Zhong Li
Feb 8, 2021·Letters in Applied Microbiology·Jun WangYi Wan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Fatima CardosoLissandra Dal Lago
American Journal of Clinical Oncology
Deborah L Toppmeyer, Susan Goodin
© 2021 Meta ULC. All rights reserved